BOSTON, April 2, 2016 /PRNewswire/ --
For non-US medical media only.
For journalistic assessment and preparation before publication.
Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide administered once-weekly, significantly improved glycaemic control compared to placebo in adults with type 2 diabetes previously managed with diet and exercise alone. Results from the SUSTAIN 1 trial were presented today at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US.
The 30-week SUSTAIN 1 trial, evaluating the efficacy and safety of semaglutide monotherapy vs placebo in 388 adults with type 2 diabetes, showed that, from a mean baseline HbA1c of 8.1%, adults treated with 0.5 mg and 1.0 mg semaglutide achieved significantly greater HbA1c reductions of 1.5% and 1.6%, respectively, vs